SB-318

N/A

Report date: 2023/10/26 16:20:43

Base Information

Drug NameSB-318
Drug Alias NameSB-318
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/6 vector
Mechanisms of ActionAlpha-L-iduronidase gene transferenceAlpha-L-iduronidase replacements
TargetsAlpha-L-iduronidase
Therapy Area/IndicationsMucopolysaccharidosis I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSangamo Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis I

Other Information

ATC CodeN/A
Related LinksN/A